Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Earnings
Travere Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 18, 2027
Q4 FY2027 · estimated, after the close
Revenue, Q3 FY2027
$224.56M
+36.2% on a year earlier
non-GAAP adjusted net loss per basic share, Q3 FY2027
-$0.31
$0.59 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Travere Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2027ended Dec 31, 2026 | Feb 18, 2027Expected | – | – | – | – | – |
| Q3 FY2027ended Sep 30, 2026 | Nov 2, 2026after the close | $224.56M | +36.2% | -$0.55 | -$0.31 | Release |
| Q2 FY2027ended Jun 30, 2026 | Aug 4, 2026after the close | $169.58M | +48.2% | -$0.37 | -$0.10 | Release |
| Q1 FY2027ended Mar 31, 2026 | May 4, 2026after the close | $127.20M | +55.6% | -$0.40 | $0.05 | Release |
| Q4 FY2026ended Dec 31, 2025 | Feb 19, 2026after the close | $129.69M | +73.4% | $0.03 | $0.37 | Release |
| Q3 FY2026ended Sep 30, 2025 | Oct 30, 2025after the close | $164.90M | +162.2% | $0.28 | $0.59 | Release |
| Q2 FY2026ended Jun 30, 2025 | Aug 6, 2025after the close | $114.40M | +111.5% | -$0.14 | $0.13 | Release |
| Q1 FY2026ended Mar 31, 2025 | May 1, 2025after the close | $81.73M | +97.5% | -$0.47 | -$0.19 | Release |
| Q4 FY2025ended Dec 31, 2024 | Feb 20, 2025after the close | $74.79M | +66.0% | -$0.73 | -$0.47 | Release |
| Q3 FY2025ended Sep 30, 2024 | Oct 31, 2024before the open | $62.90M | +69.6% | -$0.70 | -$0.46 | Release |
| Q2 FY2025ended Jun 30, 2024 | Aug 1, 2024after the close | $54.10M | -9.4% | -$0.91 | -$0.65 | Release |
| Q1 FY2025ended Mar 31, 2024 | May 6, 2024after the close | $41.37M | -27.4% | -$1.76 | -$1.51 | Release |
| Q4 FY2024ended Dec 31, 2023 | Feb 15, 2024after the close | $45.06M | -19.4% | -$1.18 | $0.94 | Release |
| Q3 FY2024ended Sep 30, 2023 | Nov 7, 2023after the close | $37.10M | -30.7% | $1.97 | $2.27 | Release |
| Q2 FY2024ended Jun 30, 2023 | Aug 3, 2023after the close | $59.70M | +10.1% | -$1.13 | -$0.77 | Release |
| Q1 FY2024ended Mar 31, 2023 | May 4, 2023after the close | $57.00M | +17.5% | -$1.27 | -$0.82 | Release |
| Q4 FY2023ended Dec 31, 2022 | Feb 23, 2023after the close | $55.90M | -2.4% | -$1.03 | -$0.76 | Release |
| Q3 FY2023ended Sep 30, 2022 | Oct 27, 2022after the close | $53.50M | -21.6% | -$1.09 | -$0.76 | Release |
| Q2 FY2023ended Jun 30, 2022 | Aug 4, 2022before the open | $54.20M | – | $1.05 | – | Release |
| Q1 FY2023ended Mar 31, 2022 | May 5, 2022after the close | $48.50M | – | -$1.20 | -$0.82 | Release |
| Q4 FY2022ended Dec 31, 2021 | Feb 24, 2022after the close | $57.25M | – | -$0.84 | -$0.61 | Release |
| Q3 FY2022ended Sep 30, 2021 | Oct 28, 2021after the close | $68.22M | – | -$0.59 | -$0.13 | Release |
| Q2 FY2022ended Jun 30, 2021 | Jul 29, 2021after the close | – | – | – | – | Filing |
| Q1 FY2022ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | – | Filing |
| Q4 FY2021ended Dec 31, 2020 | Feb 10, 2021after the close | – | – | – | – | Filing |
| Q3 FY2021ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Travere Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Travere Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Travere Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- News
- Results
See a number that looks wrong?